WO2022253819A1 - Supplement for human milk from allergic women - Google Patents
Supplement for human milk from allergic women Download PDFInfo
- Publication number
- WO2022253819A1 WO2022253819A1 PCT/EP2022/064731 EP2022064731W WO2022253819A1 WO 2022253819 A1 WO2022253819 A1 WO 2022253819A1 EP 2022064731 W EP2022064731 W EP 2022064731W WO 2022253819 A1 WO2022253819 A1 WO 2022253819A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- allergy
- free
- infant
- glutamine
- asparagine
- Prior art date
Links
- 239000013589 supplement Substances 0.000 title claims abstract description 50
- 235000020256 human milk Nutrition 0.000 title claims description 66
- 210000004251 human milk Anatomy 0.000 title claims description 66
- 208000010668 atopic eczema Diseases 0.000 title description 20
- 230000000172 allergic effect Effects 0.000 title description 19
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 171
- 208000026935 allergic disease Diseases 0.000 claims abstract description 127
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 121
- 230000007815 allergy Effects 0.000 claims abstract description 121
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 119
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 101
- 229960001230 asparagine Drugs 0.000 claims abstract description 84
- 235000013350 formula milk Nutrition 0.000 claims abstract description 67
- 235000021125 infant nutrition Nutrition 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 21
- 230000002265 prevention Effects 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims description 16
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 13
- 201000008937 atopic dermatitis Diseases 0.000 claims description 13
- 208000006673 asthma Diseases 0.000 claims description 12
- 230000009467 reduction Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 4
- 208000024711 extrinsic asthma Diseases 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 abstract description 20
- 150000001413 amino acids Chemical class 0.000 abstract description 19
- 150000001408 amides Chemical class 0.000 abstract description 11
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 230000035764 nutrition Effects 0.000 abstract description 5
- 235000013336 milk Nutrition 0.000 description 26
- 239000008267 milk Substances 0.000 description 26
- 210000004080 milk Anatomy 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 19
- 210000000481 breast Anatomy 0.000 description 11
- 230000008774 maternal effect Effects 0.000 description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
- 235000004554 glutamine Nutrition 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 6
- 206010047924 Wheezing Diseases 0.000 description 6
- 235000009582 asparagine Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 description 3
- 206010016946 Food allergy Diseases 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000020932 food allergy Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010042243 Aptamil Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 208000035756 Infantile asthma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 238000011869 Shapiro-Wilk test Methods 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- -1 aliphatic amino acids Chemical class 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 150000003857 carboxamides Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 238000005528 milk analysis Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- Field of the invention is the field of supplements or fortifiers for human milk and infant formulas, in particular for human milk from allergic mothers.
- HM Human milk
- FAAs free amino acids
- breast milk is the preferred nutrition for infants, there are maternal conditions where the breast milk composition is less optimal.
- An example is the milk from diabetic or obese mothers, that was found to be lower in levels of long chain polyunsaturated fatty acids (LC- PUFA) (Jackson et al 1994, Am J Clin Nut. 60:353-361).
- Another example is milk from mothers from preterm babies.
- Special human milk fortifiers have been developed to fortify this milk with additional ingredients, in particular protein and minerals, to enable the especially high needs for these nutrients by preterm infants.
- WO 2013/1058524 discloses glutamine-based supplement in the form of a powder. This supplement is intended for preterm or low birth weight infants and has a positive effect on brain development.
- EP 0665 012 is directed to an antiallergy agent comprising glutamine as active agent, wherein the agent is suitable for use in nutritional compositions for infants and is useful for prevention of the induction of allergic diseases in infancy, such as atopic dermatitis and infantile asthma, and the treatment thereof.
- the inventors have found that the concentration of free amide containing amino acids, asparagine and glutamine, and in particular glutamine, is significantly lower in the milk of mothers that were allergic or had a history of allergy.
- the levels of these free amide containing amino acids was furthermore associated with the health outcome in the infants in symptoms associated with allergy, such as food allergy and asthma.
- an infant formula has been developed that is enriched in the free amide containing amino acids for use in feeding infants that are at least partly breast-fed by a lactating woman that is allergic or by a lactating woman has a history of allergy, in particular by compensating for the deficit in the concentration of the free amide containing amino acids L-asparagine and/or L-glutamine in the human milk from a lactating woman that suffers from allergy or from a lactating woman that has suffered from allergy.
- the present invention relates to supplements for infant nutrition, in particular milk fortifiers, and to fortified infant formulas, in each case comprising free amide containing amino acids, L- asparagine and/or L-glutamine, in particular in unbound, that means in free form.
- the supplements for infant nutrition, in particular milk fortifiers, or the fortified infant formulas comprise at least L-glutamine, in particular free L-glutamine, more preferably L-glutamine and L-asparagine, in particular free L-glutamine and free L-asparagine.
- the supplements for infant nutrition, in particular milk fortifiers, or the fortified infant formulas comprise free amide containing amino acids consisting of L-glutamine.
- the supplements for infant nutrition in particular milk fortifiers, or fortified infant formulas according to the present invention are therefore particularly intended for use in infants that are completely or partially breast-fed by lactating women that suffer from allergy or by lactating women that have a history of allergy, such as, but not limited to hay fever, atopic dermatitis or asthma.
- a history of allergy such as, but not limited to hay fever, atopic dermatitis or asthma.
- the milk of lactating mothers suffering from allergy or of lactating mothers having a history of allergy comprises reduced levels of the free amide containing amino acids L-glutamine and L- asparagine, in particular reduced levels of L-glutamine, when compared to women that do not suffer from or have a history of allergy.
- Glutamine is a conditionally essential AA in the neonatal period and is known to have effects on the growth and function of the intestines and to modify immune responses in a favourable manner in neonatal animals, including effects that may be beneficial in terms of preventing neonatal allergies and infections ((Van den Berg et al, 2007, Arch Ped & Adol Med 161 : 1095- 1101, Sadelhoff et al, 2020, Front. Immunol., https://doi.org/10.3389/fimmu.2020.01007).
- a lower intake of free L-glutamine via human milk by infants of mothers with an history in allergic disease may have health implications on the infants and increase the risk for allergy and/or infection.
- L-asparagine can become a conditionally essential amino acid when levels of L-glutamine decline. Furthermore, the inventors found that a correlation existed between the levels of free L-asparagine and allergy related symptoms. L-glutamine and L-asparagine both have a characteristic carboxamide side chain and can be classified as free amide containing amino acids. Both are polar, aliphatic amino acids and sometimes have a similar biological function. It was found that the level of free L-asparagine in the milk inversely correlated with the occurrence of allergy. In particular, there was an inverse correlation with asthma at 6 years. L-glutamine and L-asparagine are commercially available. An example of a suitable suppliers of these ingredients is Ajinomoto (Japan).
- the present invention is particularly directed to the prevention of allergy in infants of mothers that suffer from allergy or of mothers that have a history of allergy, in particular to the prevention of allergy in infants that are completely or partially breast-fed by a lactating mother that suffers from allergy or by a lactating mother that has a history of allergy. More preferably, the present invention is directed to the prevention of allergy later in life, more preferably asthma later in life. Later in life refers to a period after breast feeding.
- the present invention pertains to a method of fortifying infant nutrition, in particular human milk from a lactating woman that suffers from allergy or from a lactating woman that has suffered from allergy or an infant formula, said method comprising the steps of: a) providing a supplement comprising L-glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine, and b) adding the supplement provided in step a) to infant nutrition, in particular human milk from a woman that suffers from allergy or from a woman that has a history of suffering from allergy or an infant formula, thereby obtaining a fortified infant nutrition, in particular a fortified human milk or a fortified infant formula.
- the fortified infant nutrition in particular the fortified human milk or the fortified infant formula, obtained in step b) is in a subsequent step c) administered, in particular fed, to an infant, preferably to an infant of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy, in particular to an infant who is at least partially fed with human milk of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy.
- the present invention is further directed to a method of providing infant nutrition to an infant of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy, in particular to an infant who is at least partially fed with human milk of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy, said method comprising the steps of: i) fortifying infant nutrition with a supplement comprising L-glutamine and/or L- asparagine, in particular free L-glutamine and/or free L-asparagine, and ii) feeding the fortified infant nutrition to the infant.
- the infant nutrition is a) human milk from a lactating woman that suffers from allergy or from a lactating woman that has suffered from allergy or b) an infant formula.
- the fortified infant nutrition is preferably either a) human milk from a lactating woman that suffers from allergy or from a lactating woman that has suffered from allergy fortified with a supplement comprising L-glutamine and/or L- asparagine, in particular free L-glutamine and/or free L-asparagine, or b) an infant formula fortified with a supplement comprising L-glutamine and/or L-asparagine, in particular free L- glutamine and/or free L-asparagine.
- the supplement comprising L-glutamine and/or L-asparagine in particular free L-glutamine and/or free L-asparagine
- the supplement comprising L-glutamine and/or L-asparagine, in particular free L- glutamine and/or free L-asparagine is a supplement for infant formulas.
- the supplement comprising L-glutamine and/or L-asparagine, in particular free L- glutamine and/or free L-asparagine, or the infant formula fortified with a supplement comprising L-glutamine and/or L-asparagine, in particular free L-glutamine and/or free L- asparagine, is in powder form.
- the fortified infant nutrition contains L- glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine, in an amount of at least 8.5 mg/100 ml, preferably at least 9 mg/100 ml, preferably, preferably at least 10 mg/100 ml, preferably at least 15 mg/100 ml, preferably at least 20 mg/ 100 ml, preferably at least 25 mg/100 ml, preferably at least 30 mg/100 ml, preferably at least 40 mg/100 ml, preferably at least 50 mg/100 ml.
- the fortified infant nutrition contains L- glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine, in an amount of at most 800 mg/100 ml, preferably at most 500 mg/100 ml, preferably at most 250 mg/ 100 ml, preferably at most 100 mg/100 ml, preferably at most 80 mg/100 ml, preferably at most 60 mg/100 ml, preferably at most 40 mg/100 ml.
- L- glutamine and/or L-asparagine in particular free L-glutamine and/or free L-asparagine, in an amount of at most 800 mg/100 ml, preferably at most 500 mg/100 ml, preferably at most 250 mg/ 100 ml, preferably at most 100 mg/100 ml, preferably at most 80 mg/100 ml, preferably at most 60 mg/100 ml, preferably at most 40 mg/100 ml.
- the invention also pertains to the use of a supplement comprising L-glutamine and/or L- asparagine, in particular free L-glutamine and/or free L-asparagine, for fortifying infant nutrition of an infant of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy, in particular an infant who is at least partially fed with human milk of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy.
- a supplement comprising L-glutamine and/or L- asparagine, in particular free L-glutamine and/or free L-asparagine
- the supplement used for fortifying infant nutrition of an infant of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy provides the infant nutrition with L-glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine, in an amount of at least 8.5 mg/100 ml, preferably at least 9 mg/100 ml, preferably, preferably at least 10 mg/100 ml, preferably at least 15 mg/100 ml, preferably at least 20 mg/ 100 ml, preferably at least 25 mg/100 ml, preferably at least 30 mg/100 ml, preferably at least 40 mg/100 ml, preferably at least 50 mg/100 ml.
- the milk fortifier used for fortifying infant nutrition of an infant of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy provides the infant nutrition with L-glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine, in an amount of at most 800 mg/100 ml, preferably at most 500 mg/100 ml, preferably at most 250 mg/ 100 ml, preferably at most 100 mg/100 ml, preferably at most 80 mg/100 ml, preferably at most 60 mg/100 ml, preferably at most 40 mg/100 ml.
- the infant nutrition fortified with the supplement comprising L-glutamine and/or L-asparagine in particular free L-glutamine and/or free L-asparagine
- the infant nutrition fortified with the supplement comprising L-glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine is an infant formula.
- the present invention is also directed to a supplement comprising L-glutamine and/or L- asparagine, in particular free L-glutamine and/or free L-asparagine, preferably at least L- glutamine, in particular free L-glutamine, in particular to a supplement comprising L-glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine, preferably at least L-glutamine, in particular free L-glutamine, for use in the treatment or prevention of allergy, in particular for use in the treatment or prevention or reduction of the risk of allergy, in an infant of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy, in particular wherein the infant is at least partially fed with the human milk of the lactating woman.
- the supplement is packed in unit dose, e.g. in the form of sachets.
- each sachet contains the amount of L-glutamine and/or L- asparagine, in particular free L-glutamine and/or free L-asparagine, to supplement 100 ml of infant formula or expressed human milk.
- one sachet contains at least 8 mg L- glutamine, in particular free L-glutamine, more preferably at least 20 mg L-glutamine, in particular free L-glutamine.
- L-asparagine, in particular free L-asparagine is present in the fortifier in an amount of 0.8 to 2 mg per sachet.
- the L-glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine, are preferably mixed with a carrier, such as maltodextrin or starch, in order to facilitate an accurate dosing.
- a carrier such as maltodextrin or starch
- the sachet may contain 500 mg of which 25 mg L-glutamine, in particular free L-glutamine, 5 mg L-asparagine, in particular free L-asparagine, and the remainder 470 mg maltodextrin or starch.
- the maximal amount of the sum of L-glutamine and L-asparagine, in particular free L-glutamine and/or free L-asparagine is preferably 500 mg per sachet.
- the supplement can particularly be used to fortify infant nutrition, in particular expressed human milk from mothers that suffer from allergy or from mothers that have a history of allergy or an infant formula.
- the fortified infant nutrition in particular the fortified expressed human milk from mothers that suffer from allergy or from mothers that have a history of allergy or the fortified infant formula, is administered to the infant at least once a day, preferably at least twice a day.
- the supplement comprising L-glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine can also be used to fortify standard infant formula, in particular standard infant formula that is intended for infants that are at least partially breast-fed by lactating women suffering from allergy or by lactating women having a history of allergy.
- standard infant formula that is intended for infants that are at least partially breast-fed by lactating women suffering from allergy or by lactating women having a history of allergy.
- Partially breast-fed infants are defined as infants receiving at least once a day breast feeding and at least once a day a feeding with infant formula.
- Standard infant formula based on intact cow’s milk protein, contains very low levels of free amino acids, in particular very low levels of free L-glutamine and L-asparagine compared to human milk (see Chuang et ah, 2005, JPGN 40:496-500, and Agostoni et ah, 2000, Journal of the American College of Nutrition, Vol. 19, No. 4, 434-438).
- the present invention therefore also pertains to an infant formula fortified with L-glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine, preferably at least L-glutamine, in particular free L-glutamine, in particular to an infant formula fortified with L- glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine, preferably at least L-glutamine, in particular free L-glutamine, for use in the treatment or prevention of allergy, in particular for use in the treatment or prevention or reduction of the risk of allergy, in an infant of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy, in particular wherein the infant is at least partially fed with the human milk of the lactating woman.
- the infant formula in particular the infant formula for use in the treatment or prevention of allergy, in particular for use in the treatment or prevention or reduction of the risk of allergy, in an infant of a lactating woman that suffers from allergy or of lactating woman that has suffered from allergy, comprises L-glutamine and/or L-asparagine, in particular free L- glutamine and/or free L-asparagine, in an amount of at least 8.5 mg/100 ml, preferably at least 9 mg/100 ml, preferably, preferably at least 10 mg/100 ml, preferably at least 15 mg/100 ml, preferably at least 20 mg/ 100 ml, preferably at least 25 mg/100 ml, preferably at least 30 mg/100 ml, preferably at least 40 mg/100 ml, preferably at least 50 mg/100 ml, when the infant formula is in liquid form or reconstituted in water from a powder to a ready -to-drink formula.
- the infant formula in particular the infant formula for use in the treatment or prevention of allergy, in particular for use in the treatment or prevention or reduction of the risk of allergy, in an infant of a lactating woman that suffers from allergy or of lactating woman that has suffered from allergy, comprises L-glutamine and/or L-asparagine, in particular free L-glutamine and/or free L-asparagine, in an amount of at most 800 mg/100 ml, preferably at most 500 mg/ 100 ml, preferably at most 250 mg/100 ml, preferably at most 100 mg/100 ml, preferably at most 80 mg/100 ml, preferably at most 60 mg/100 ml, preferably at most 40 mg/100 ml.
- the amount of L-glutamine, in particular free L-glutamine, in the fortified infant formula is preferably at least 8 mg/100 ml, more preferably at least 15 mg/100 ml, when the infant formula is in liquid form or reconstituted in water from a powder to a ready-to-drink formula.
- the amount of the sum of L-glutamine and L-asparagine, in particular free L-glutamine and free L- asparagine, in the fortified infant formula is preferably not more than 800 mg/100 ml, more preferably not more than 100 mg/100 ml, when the infant formula is in liquid form or reconstituted in water from a powder to a ready-to-drink formula.
- the amount of L-glutamine, in particular free L-glutamine, in the fortified infant formula is preferably not more than 800 mg/100 ml, more preferably not more than 100 mg/100 ml when the infant formula is in liquid form or reconstituted in water from a powder to a ready-to-drink formula.
- the fortified infant nutrition in particular the fortified human milk or the fortified infant formula, comprises L-glutamine and L-asparagine, in particular free L-glutamine and free L-asparagine, in a weight ratio of 50/1 to 5/1, preferably 45/1 to 6/1, more preferably 40/1 to 7/1.
- the supplement or the infant nutrition in particular the supplement or the infant formula for use in the treatment or prevention of allergy, in particular for use in the treatment or prevention or reduction of the risk of allergy, in an infant of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy, comprises L-glutamine and L-asparagine, in particular free L-glutamine and free L-asparagine, in a weight ratio of 50/1 to 5/1, preferably 45/1 to 6/1, more preferably 40/1 to 7/1. This ratio reflects the ratio as observed in milk from non-allergic mothers.
- the fortified infant nutrition in particular the fortified human milk or the fortified infant formula, is administered to the infant.
- the supplement comprising L- glutamine and/or L-asparagine, in particular free L-glutamine and free L-asparagine, or the fortified infant formula is in powder form.
- L-glutamine and L-asparagine have a limited stability in aqueous solutions.
- the L-glutamine and/or L-asparagine degradation is limited.
- the infant is a term infant.
- the infant has a birth weight appropriate for gestational age.
- the infant is a term infant and has a birth weight appropriate for gestational age.
- infants are defined as human subjects with an age of 0 to 12 months.
- the infant has an age of 3 to 12 month, more preferably an age of 6 to 12 months.
- Atopic dermatitis the first onset in the atopic march typically first appears after 3 to 6 months of age.
- the infant is at risk of allergy. Infants at risk for allergy particularly benefit from the invention.
- the allergy in particular the allergy the lactating mother is suffering from or has suffered from, is selected from hay fever, atopic dermatitis and asthma.
- the term “comprising” preferably has the meaning of “containing” or “including” meaning that the composition in question at least comprises the specifically identified component without excluding the presence of further components.
- the term comprising is also understood to have the meaning of “consisting essentially of’ and in a most preferred embodiment of “consisting”.
- the term “consisting essentially of’ excludes the presence of substantial amounts of further components except the specifically identified component of the composition.
- the term “consisting” excludes the presence of any further compound, no matter in which quantity in the composition identified.
- Example 1 Breast milk analysis study: Breast milk from allergic mothers has a reduced content of free glutamine and asparagine.
- HM samples were collected at approximately 6 months post-delivery. Mothers were instructed to manually express or pump the first ⁇ 10 mL of HM (i.e. foremilk) between 9am and 12pm, after breakfast and before lunch but at least one-hour after the last feeding. In rare instances, trained study nurses helped mothers with expression. Mothers stored the HM samples in the refrigerator until study nurses collected the samples and delivered them to the study centre. Amino acid analyses
- HM samples were stored at -80°C until analysis of AAs.
- Levels of FAAs ⁇ i.e. unbound AAs) and TAAs ⁇ i.e. unbound + conjugated AAs) were analysed by liquid chromatography as described in detail in Sadelhoff, et al., Nutrients, 2018. 10(9) 1233; doi: 10.3390/nul0091233. This method disabled the detection of proline and cysteine, yielding a total of 18 detectable FAAs and taurine, ornithine and citrulline.
- the measurements of TAAs required acidic hydrolysis of proteins, which enabled the detection of 15 TAAs and disabled the detection of tryptophan, cysteine, and proline.
- the acidic hydrolysis process also transformed asparagine into aspartate and glutamine into glutamate, disabling the detection of these TAAs individually. All measurements were done in the same lab and by the same technician.
- Maternal allergy was self-reported and classified as mothers who reported a history of hay fever, atopic dermatitis or asthma. Non-allergic mothers reported the absence of an allergic disease.
- a reported doctor’s diagnosis of wheeze in the past 12 months was assessed at 1 year, 2 years and at each yearly follow-up by separate self-administered questionnaires from parents. Wheezing phenotypes were classified into three categories: transient (report of wheeze at age 1 but not at age 2 and 3), persistent (report of wheeze at age 2 but not age 1 and 3) and late onset (report of wheeze at age 1, 2 and 3).
- Atopic dermatitis (AD) status was assessed by separate parent and paediatrician reports of doctor-diagnosed AD assessed at 1, 2 and 3 years post-delivery.
- AD was analysed separately as “parent-only”, “paediatrician-only” and “both parent and paediatrician” reported AD diagnosis. Children with at least one positive report of AD were defined as cases in the relevant outcome category.
- a reported doctor’s diagnosis of food allergy in the past 12 months was assessed at 1 year of age by separate self-administered questionnaires from parents and the children’s primary care paediatricians.
- Lower respiratory tract infections including pneumonia, bronchitis, pertussis, tracheobronchitis, Krupp, bronchiolitis and flu
- Asthma was assessed at 6 years of age.
- HM samples for AA analyses were available from 441 lactating women at 6 months of lactation. At this timepoint, 167 mothers (37.7%) were reported to be allergic or have a history of allergy.
- Table 1 FAA levels in HM of mothers with and without history in allergic disease
- FAA free amino acid
- Modified Poisson Regression revealed a significant association between free asparagine and asthma. Asthma was assessed at 6 years of life and a significant negative association was found with the level of free asparagine in the human milk 0.78 (RR 95% Cl 0.68; 0.90, p ⁇ 0.05). Together with the known positive effects of L-glutamine on immune and intestinal epithelial cells, resulting in positive effects on preventing infection, inflammation and allergy, this is indicative for a preventive effect on allergy, including asthma later in life, by these amino acids.
- Example 2 Milk fortifier for infants partially or completely breast-fed by allergic mothers or mothers with a history of allergy.
- a milk fortifier A is packet in a sachet.
- the milk fortifier A is in powder form and comprises about 50 mg L-glutamine per sachet, and the remainder, up to 500 mg, being a suitable carrier like maltodextrin.
- a milk fortifier B is packet in a sachet.
- the milk fortifier B is in powder form and comprises about 50 mg L-glutamine per sachet and 5 mg of L-asparagine, and the remainder, up to 500 mg, being a suitable carrier like maltodextrin.
- Example 3 Method for supplementing human milk from a lactating woman that suffers from allergy or has a history of allergy.
- Milk is expressed by a lactating woman that is allergic or has a history of allergy.
- Example 4 Method for supplementing an infant formula for and infant partially breast-fed by a lactating woman that suffers from allergy or has a history of allergy.
- a standard infant formula containing intact cow’s milk protein (whey protein/casein in 6/4 weight ratio, 2.0 g protein per 100 kcal, about 1.35 g protein per 100 ml ready to drink formula) is prepared in a bottle.
- One sachet of the milk fortifier supplement A or B of example 2 is added to the bottle, mixed with the infant formula and fed to the infant, preferably at least once a day.
- Example 5 Supplemented infant formula for an infant partially breast fed by a lactating woman that suffers from allergy or has a history of allergy.
- Standard infant formula is manufactured as known in the art, in compliance with international directives for infant formula.
- the protein component is intact protein derived from cow’s milk protein (whey protein concentrate and skim milk powder) and contains whey protein/casein in a 6/4 weight ratio.
- the amount of protein is 2.0 g/100 kcal.
- the infant formula is in powder form and contains 276 kcal/ 100 gram. When the powder is reconstituted to a ready -to-drink formula the amount of kcal per 100 ml is 66.
- Free L-glutamine is added to this powdered infant formula in an amount of 75 mg/100 g powder. Without addition of free L-glutamine the amount of L-glutamine would have been below 3.75 mg per 100 g powder in accordance with the levels found for Nutrilon and Aptamil in Agostoni et al, 2000, Journal of the American College of Nutrition, Vol. 19, No. 4, 434-438 (33 pmol/l or less in reconstituted ready -to-drink form).
- the infant formula is particularly intended for infants that are partially breast-fed by mothers that suffer or have suffered from allergy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pediatric Medicine (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dairy Products (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280035311.4A CN117460426A (en) | 2021-06-02 | 2022-05-31 | Supplement for breast milk of allergic women |
EP22730911.9A EP4346443A1 (en) | 2021-06-02 | 2022-05-31 | Supplement for human milk from allergic women |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21177471.6 | 2021-06-02 | ||
EP21177471 | 2021-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022253819A1 true WO2022253819A1 (en) | 2022-12-08 |
Family
ID=76250248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/064731 WO2022253819A1 (en) | 2021-06-02 | 2022-05-31 | Supplement for human milk from allergic women |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4346443A1 (en) |
CN (1) | CN117460426A (en) |
WO (1) | WO2022253819A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0665012A1 (en) | 1994-01-31 | 1995-08-02 | Snow Brand Milk Products Co., Ltd. | Antiallergy agent and nutritional composition containing glutamine and process for the production thereof |
AU2011100142A4 (en) * | 2011-02-02 | 2011-03-03 | Abbott Laboratories | Infant Formula: Probiotic Supplementation |
WO2013058524A1 (en) | 2011-10-18 | 2013-04-25 | Lg Innotek Co., Ltd. | Solar cell apparatus and method of fabricating the same |
US20140370155A1 (en) * | 2011-12-30 | 2014-12-18 | Abbott Laboratories | Stabilized concentrated liquid human milk fortifier |
US20170042849A1 (en) * | 2014-04-17 | 2017-02-16 | N.V. Nutricia | Composition for brain improvement |
US20190076490A1 (en) * | 2012-11-02 | 2019-03-14 | N.V. Nutricia | Synbiotics combination for brain improvement |
-
2022
- 2022-05-31 WO PCT/EP2022/064731 patent/WO2022253819A1/en active Application Filing
- 2022-05-31 CN CN202280035311.4A patent/CN117460426A/en active Pending
- 2022-05-31 EP EP22730911.9A patent/EP4346443A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0665012A1 (en) | 1994-01-31 | 1995-08-02 | Snow Brand Milk Products Co., Ltd. | Antiallergy agent and nutritional composition containing glutamine and process for the production thereof |
EP0665012B1 (en) * | 1994-01-31 | 2001-09-19 | Snow Brand Milk Products Co., Ltd. | Antiallergy agent and nutritional composition containing glutamine |
AU2011100142A4 (en) * | 2011-02-02 | 2011-03-03 | Abbott Laboratories | Infant Formula: Probiotic Supplementation |
WO2013058524A1 (en) | 2011-10-18 | 2013-04-25 | Lg Innotek Co., Ltd. | Solar cell apparatus and method of fabricating the same |
US20140370155A1 (en) * | 2011-12-30 | 2014-12-18 | Abbott Laboratories | Stabilized concentrated liquid human milk fortifier |
US20190076490A1 (en) * | 2012-11-02 | 2019-03-14 | N.V. Nutricia | Synbiotics combination for brain improvement |
US20170042849A1 (en) * | 2014-04-17 | 2017-02-16 | N.V. Nutricia | Composition for brain improvement |
Non-Patent Citations (8)
Title |
---|
AGOSTONI ET AL., JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, vol. 19, no. 4, 2000, pages 434 - 438 |
CHUANG ET AL., JPGN, vol. 40, 2005, pages 496 - 500 |
HETTINGA ET AL., PLOS ONE, 2015 |
JACKSON ET AL., AM J CLIN NUT., vol. 60, 1994, pages 353 - 361 |
LOGAN, C. ET AL., PEDIATRICS, vol. 137, 2016, pages e20154473 |
SADELHOFF ET AL., FRONT. IMMUNOL., 2020, Retrieved from the Internet <URL:https://doi.org/10.3389/fimmu.2020.01007> |
SADELHOFF, J.H.J. ET AL., NUTRIENTS, vol. 10, no. 9, 2018, pages 1233 |
VAN DEN BERG ET AL., ARCH PED & ADOL MED, vol. 161, 2007, pages 1095 - 1101 |
Also Published As
Publication number | Publication date |
---|---|
CN117460426A (en) | 2024-01-26 |
EP4346443A1 (en) | 2024-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lestari et al. | Correlation between non-exclusive breastfeeding and low birth weight to stunting in children | |
Mulrine et al. | Breast-milk iodine concentration declines over the first 6 mo postpartum in iodine-deficient women | |
Pisacane et al. | Iron status in breast-fed infants | |
Male et al. | Prevalence of iron deficiency in 12‐mo‐old infants from 11 European areas and influence of dietary factors on iron status (Euro‐Growth study) | |
Menon et al. | Effects of anemia at different stages of gestation on infant outcomes | |
Andersson et al. | Effectiveness of increased salt iodine concentration on iodine status: trend analysis of cross-sectional national studies in Switzerland | |
Kikafunda et al. | Anaemia and associated factors among under-fives and their mothers in Bushenyi district, Western Uganda | |
Neumann et al. | Low vitamin B12 intake during pregnancy and lactation and low breastmilk vitamin B12 content in rural Kenyan women consuming predominantly maize diets | |
Konrade et al. | Iodine deficiency during pregnancy: a national cross-sectional survey in Latvia | |
Cichon et al. | Impact of food supplements on hemoglobin, iron status, and inflammation in children with moderate acute malnutrition: a 2× 2× 3 factorial randomized trial in Burkina Faso | |
Shehadeh et al. | Insulin in human milk: postpartum changes and effect of gestational age | |
Heinig et al. | Zinc supplementation does not affect growth, morbidity, or motor development of US term breastfed infants at 4–10 mo of age | |
Tan et al. | Case study of temporal changes in maternal dietary intake and the association with breast milk mineral contents | |
ES2886647T3 (en) | Betacaseins and cognitive function | |
Shapira et al. | Deletion of the short arm of chromosome 10 (10p13): report of a patient and review | |
EP4346443A1 (en) | Supplement for human milk from allergic women | |
Onwuneme et al. | Correction of vitamin D deficiency in a cohort of newborn infants using daily 200 IU vitamin D supplementation | |
Fabunmi et al. | Nutrient intakes and nutritional status of mothers and their under-five children in a rural community of Oyo state, Nigeria | |
Kemi et al. | Breastfeeding and child spacing among women in South West Nigeria | |
Ercan et al. | Relationship between newborn craniotabes and vitamin D status | |
US11925197B2 (en) | Beta-caseins and gut microbiota | |
Tawfeek et al. | Effect of maternal dietary vitamin C intake on the level of vitamin C in breastmilk among nursing mothers in Baghdad, Iraq | |
Lubree et al. | Child's homocysteine concentration at 2 years is influenced by pregnancy vitamin B12 and folate status | |
Willows et al. | Serum retinol is associated with hemoglobin concentration in infants who are not vitamin A deficient | |
Sibeko et al. | Full-term, peri-urban South African infants under 6 months of age are at risk for early-onset anaemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22730911 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280035311.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022730911 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022730911 Country of ref document: EP Effective date: 20240102 |